{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.5","value":"732"},{"groupId":"OG002","spread":"1.9","value":"1149"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"The maximum concentration of M6620 in the blood when aprepitant is also given.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received M6620 (VX-970, berzosertib) 120 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.","id":"OG000","title":"Dose Level 1"},{"description":"Patients received M6620 (VX-970, berzosertib) 160 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.","id":"OG001","title":"Dose Level 2"},{"description":"Patients received M6620 (VX-970, berzosertib) 200 mg/m2 by infusion in their arm weekly, cisplatin 40 mg/m2 IV weekly starting a week after M6620, and radiation therapy 70 Gy daily Monday-Friday also starting a week after M6620.","id":"OG002","title":"Dose Level 3"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Based on samples collected. PK was only collected in the dose escalation phase. PK was not collected for participants in the dose expansion arm.","reportingStatus":"POSTED","timeFrame":"Up to Day 5","title":"Potential Drug-drug Interaction","type":"SECONDARY","unitOfMeasure":"ug/L"}